Form 4: Cryo-Cell Co-CEO Portnoy Buys Shares

Cryo-Cell International Inc.'s Chairman and Co-CEO, David Portnoy, acquired 5,826 shares of common stock at $4.1719 per share, increasing his beneficial ownership.

Summary

• David Portnoy, Chairman, Co-CEO, and a 10% owner of Cryo-Cell International Inc. (CCEL), acquired 5,826 shares of the company's common stock.
• The shares were purchased on August 14, 2025, at a price of $4.1719 per share.
• Following this transaction, Portnoy's total beneficial ownership of non-derivative common stock stands at 1,576,903 shares, held directly and indirectly through various entities including a 401K, IRA, spouse, corporations (Mayim Limited Partnership and uTIPu, Inc.), an LLC, and as custodian for children.
• Portnoy also holds 529,879 derivative shares in the form of stock options with exercise prices ranging from $4.30 to $12.27, and various vesting schedules, including performance-based vesting if the stock reaches $25.00 per share.

Sentiment

Score: 8

Explanation: The purchase of shares by a high-level insider (Chairman, Co-CEO, and 10% owner) indicates strong confidence in the company's valuation and future prospects. This is generally a very positive signal for investors.

Positives

• A key insider, David Portnoy (Chairman, Co-CEO, and 10% owner), purchased additional shares, signaling confidence in the company's future prospects.
• The purchase price of $4.1719 per share indicates management's belief in the stock's value at this level.
• The acquisition increases the alignment of management's interests with those of shareholders.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing, an insider stock purchase, is specific to Cryo-Cell International Inc. and David Portnoy's investment decision. It does not provide broader industry trends or competitive analysis.

Related Party Transactions

• The filing details indirect beneficial ownership through entities like Mayim Limited Partnership and uTIPu, Inc., where David Portnoy may be deemed the beneficial owner. These represent existing structures for holding shares rather than new related party transactions.

Stakeholder Impact

• Shareholders: The insider purchase may instill greater confidence among existing shareholders and attract new investors, potentially leading to increased demand for the stock.
• Management/Employees: The increased stake by a key executive reinforces alignment between management and shareholder interests.

Next Steps

• The filing details vesting schedules for various stock options held by David Portnoy, with future vesting dates extending into 2027.

Key Dates

Recommendation

The purchase of shares by a high-ranking insider, who is also a significant owner, signals strong conviction in the company's intrinsic value and future growth potential. Such insider buying often precedes positive developments or reflects a belief that the stock is undervalued, making it a compelling 'buy' signal for seasoned investors.

Keywords

Cryo-Cell International, CCEL, David Portnoy, Insider Trading, Stock Purchase, SEC Form 4, Beneficial Ownership, Stock Options, Biotechnology, Stem Cell Banking